ASX Share rice
Sat 08 Aug 2020 - 07:36:pm (Sydney)

NXS Share Price

NEXT SCIENCE LIMITEDNXSHealth Care Equipment & Services

NXS Company Information

Name:

Next Science Limited

Sector:

Healthcare

Industry:

Drug Manufacturers—Specialty & Generic

Address:

The Zenith Building Tower A Sydney NSW Australia 2067

Phone:

61 2 8607 5124

MD, CEO & Director:

Ms. Judith Mitchell M.B.A.

Founder & CTO:

Dr. Matthew Myntti

Chief Financial Officer:

Ms. Jacqueline Butler CA (ICAEW)

Chief Operating Officer:

Mr. Jon Swanson

Chief Commercial Officer:

Mr. Dustin Haines

Company Overview:

Next Science Limited, a medical technology company, researches, develops, and commercializes non-toxic technology products with efficacy in eradicating biofilm based and free-floating bacteria in the United States and Australia. The company develops its products using its Xbio Technology platform. It offers SurgX, an innovative surgical gel designed to reduce superficial surgical site infections and protect wound tissue to facilitate natural healing; and Bactisure, a surgical lavage that is used to remove debris, including microorganisms from wounds. The company also provides BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment. In addition, it is developing acne cream and cleanser. Next Science Limited was founded in 2012 and is headquartered in Sydney, Australia.

NXS Share Price Information

Shares Issued:

181.24M

Market Capitalisation:

$230.18M

Revenue (TTM):

$4.06M

Revenue Per Share (TTM):

$0.02

Earnings per Share:

$-0.08

Operating Margin (TTM):

$-3.08

Return On Assets (TTM):

$-0.47

Return On Equity (TTM):

$-1.45

Quarterly Revenue Growth (YOY):

-0.19

Gross Profit(TTM):

$3.51M

Diluted Earnings Per Share (TTM):

$-0.086

NXS CashFlow Statement

CashFlow Date:

2019-12-31

Investments:

$-2,295,209.82

Change To Liabilities:

$-219,847

Total Cashflow From Investing Activities:

$-1,608,024

Net Borrowings:

$-139,536

Net Income:

$-20,485,052.81

Total Cash From Operating Activities:

$-12,331,556

Depreciation:

$458.74K

Change To Inventory:

$-223,094

Change To Account Receivables:

$-578,351

Sale Purchase Of Stock:

$-2,452,182.42

Capital Expenditures:

$2.30M

NXS Income Statement

Income Date:

2019-12-31

Income Before Tax:

$-20,485,052.81

Net Income:

$-20,485,052.81

Gross Profit:

$5.01M

Operating Income:

$-17,893,929.49

Other Operating Expenses:

$-35,365

Interest Expense:

$3M

Total Revenue:

$5.80M

Total Operating Expenses:

$22.90M

Cost Of Revenue:

$785.73K

NXS Balance Sheet

Balance Sheet Date:

2019-12-31

Intangible Assets:

$3.09M

Total Liabilities:

$4.76M

Total Stockholder Equity:

$27.64M

Other Current Liabilities:

$535.41K

Total Assets:

$32.40M

Common Stock:

$90.69M

Other Current Assets:

$332.50K

Retained Earnings:

$-41,655,094.21

Other Liabilities:

$1.33M

Other Assets:

$1.32M

Cash:

$24.14M

Total Current Liabilities:

$2.45M

Property - Plant & Equipment:

$1.21M

Net Tangible Assets:

$18.49M

Total Current Assets:

$27.52M

Net Receivables:

$2.08M

Short-Term Investments:

$4.88M

Inventory:

$571.45K

Accounts Payable:

$896.42K

Non Currrent Assets (Other):

$4.88M

Short-Term Investments:

$4.88

Non Current Liabilities (Other):

$1.90M

Non Current Liabilities Total:

$2.31M

NXS Share Price History

NXS News

24 Jul, 2020
Today is shaping up negative for Next Science Limited (ASX:NXS) shareholders, with the analysts delivering a...
03 Jul, 2020
Next Science Limited's (ASX:NXS): Next Science Limited, a medical technology company, researches, develops, and...
04 May, 2020
Over the last month the Next Science Limited (ASX:NXS) has been much stronger than before, rebounding by 48%. But that...
23 Mar, 2020
Full Year 2019 Next Science Ltd Earnings Call